Inventors:
Michelle Bradbury - New York NY, US
Ulrich Wiesner - Ithaca NY, US
Oula Penate Medina - New York NY, US
Andrew Burns - Niskayuna NY, US
Jason Lewis - New York NY, US
Steven Larson - New York NY, US
Assignee:
CORNELL UNIVERSITY - Ithaca NY
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY
International Classification:
A61K 49/00, A61K 49/06, A61K 49/04, A61K 9/14, A61K 39/395, A61K 31/7088, A61K 48/00, A61K 31/56, A61K 31/713, A61K 31/7105, G01N 21/64, A61P 35/00, A61P 31/04, A61P 31/00, A61P 39/06, A61P 37/06, A61P 7/02, A61P 9/08, A61P 29/00, A61K 51/12, B82Y 5/00, B82Y 15/00
US Classification:
424 137, 424 96, 424 93, 424 94, 424490, 4241781, 514 44 A, 514 44 R, 514169, 435 723, 977773, 977906, 977927, 977928, 977930
Abstract:
The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques.